Table of Contents
ISRN Oncology
Volume 2011, Article ID 523915, 7 pages
Research Article

Serum Natrium Determines Outcome of Treatment of Advanced GIST with Imatinib: A Retrospective Study of 80 Patients from a Single Institution

1Department of Oncology, Aarhus University Hospital, Nørrebrogade 44, 8000 Aarhus C, Denmark
2Department of Surgery, Aarhus University Hospital, Nørrebrogade 44, 8000 Aarhus C, Denmark
3Department of Pathology, Aarhus University Hospital, Nørrebrogade 44, 8000 Aarhus C, Denmark
4Oncology Department, College of Medicine, King Saud University, 11411 Riyadh, Saudi Arabia

Received 29 May 2011; Accepted 11 July 2011

Academic Editors: C. N. Qian and L. Saragoni

Copyright © 2011 Ninna Aggerholm-Pedersen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Treatment with tyrosine kinase inhibitors (TKIs) has drastically improved overall survival (OS) of patients with advanced GIST. The aim of this study is to evaluate the results of treatment with different TKIs on advanced GIST and identify prognostic factors for OS. The medical records of all patients treated at the Department of Oncology, Aarhus University Hospital were retrospectively reviewed. Between 2001 and 2009, 80 patients with advanced GIST were treated with imatinib as first-line therapy. The median OS was 44 months (95% CI 31–56), and the 5-year OS was 40%. Since 2005, 32 patients were treated with sunitinib as 2nd-line therapy. The median time to progression was 9 months (95% CI: 3–13 months), and the 3-year OS was 30%. The data illustrate that data from large multicenter studies are reproducible in a single sarcoma centre. This retrospective study pointed to low serum sodium at the start of imatinib as a possible prognostic factor affecting OS.